|
December 2007
Atlantic Research Group, Inc. implements its Clinical Trial Management System TrialVista® for the Hereditary Angioedema Association's (HAEA) patient reported outcome trial of home vs. hospital treatment of HAE.
November 2007
Atlantic Research Group, Inc. was awarded a clinical services management contract for a Phase II study for intradialytic hypotension in hemodialysis patients. The study will include 15 investigative sites and will enroll 75 patients.
September 2007
Atlantic Research Group Successfully Completes Work on Phase III Randomized, Multi-Center Clinical Trial Facilitating Lev Pharmaceuticals' BLA Submission
July 2007
Biotech Trends Hit the Valley July 13, 2007
July 2007
Research Company Partners with Grads July 11, 2007
May 2007
Atlantic Research Group, Inc. has successfully completed enrollment of all subjects in Lev Pharmaceutical's pivotal Phase III trial of Cinryze (C1 inhibitor) for the prophylactic treatment of hereditary angioedema (HAE).
April 2007
Staunton Pharmaceutical Company Set to Expand April 27, 2007
December 2006
Atlantic Research Group, Inc. has successfully completed enrollment of all subjects in Lev Pharmaceutical's pivotal Phase III trial of Cinryze™ (C1 inhibitor) for the acute treatment of hereditary angioedema (HAE).
December 2006
Atlantic Research Group, Inc. has successfully completed enrollment of all subjects in Lev Pharmaceutical's pivotal Phase III trial of Cinryze™ (C1 inhibitor) for the acute treatment of hereditary angioedema (HAE).
October 2006
Atlantic Research Group, Inc. obtains clinical monitoring services contract for Phase I trial of a monoclonal antibody in mesothelioma patients (3 sites 25+ patients) and Phase II trial of a monoclonal antibody (15 sites 60 patients) in ovarian cancer patients.
October 2006
Atlantic Research Group, Inc. implements its Clinical Trial Management System, TrialVista®, for a Phase II trial of a monoclonal antibody in ovarian cancer. The enrollment for the Phase II trial is tripled in 3 months.
July 2006
Atlantic Research Group, Inc. obtains contract for the clinical monitoring services for a Phase I trial of a monoclonal antibody in Ovarian Cancer. Atlantic Research Group successfully managed one investigative site which enrolled over 30 patients.
June 2006
Atlantic Research Group obtains contract for all clinical and project management services for Lev Pharmaceutical's new trials of Cinryze™ (C1 inhibitor) for the acute and prophylactic treatment of hereditary angioedema (HAE). All clinical and project management services for the rollover studies associated with these trials have also been awarded to Atlantic Research Group, Inc.
September 2005
Atlantic Research Group, Inc. is awarded a $20,000 incentive grant from the Staunton Industrial Development Authority. Virginia Business Magazine, September 2005
June 2005
Atlantic Research Group, Inc. obtains contract for the clinical monitoring services role for Lev Pharmaceutical's pivotal Phase III trials of Cinryze™ (C1 inhibitor) for the acute and prophylactic treatment of hereditary angioedema (HAE). 70 investigative site and 200 enrolled patients were successfully managed by Atlantic Research Group.
May 2005
Atlantic Research Group, Inc. obtains contract for partial clinical monitoring services for a Phase III trial for prostate cancer. 8 investigative sites and 25 patients were successfully managed by Atlantic Research Group. |
